Xencor Inc (XNCR) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.

Total Revenue Chart for Xencor Inc

Xencor Inc (XNCR) revenue for FY2025 was USD 125.6M, a 13.7% change from FY2024. Xencor Inc's revenue grew from USD 6.8M in 2011 to USD 125.6M in 2025 (1733.5% over 14 years). Earnings per share moved from USD -0.52 in 2014 to USD -0.93 in 2022. Revenue compound annual growth rate: 5-year CAGR of 0.5%, 10-year CAGR of 16.3%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.70B
Implied Share Price
$22.85
Enterprise Value
$1.52B
Revenue (TTM)
$104.97M
EBITDA
-$205.90M
Profit Margin
-155.59%
Trailing P/E
—
Forward P/E
68.03
Price/Book (MRQ)
3.58
Price/Sales (TTM)
16.18
EV/EBITDA
-17.27
EV/Revenue
14.45
Dividend Yield
—
Book Value
$6.77
Free Cash Flow (FY2025)
-$138.27M
Free Cash Flow Yield
-8.14%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.